A5102894036- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Complement system in diseases
- Biochemical and Molecular Research
- Blood groups and transfusion
- Renal Transplantation Outcomes and Treatments
- Microbial Inactivation Methods
- Chronic Lymphocytic Leukemia Research
- Toxin Mechanisms and Immunotoxins
- Blood transfusion and management
- TGF-β signaling in diseases
- Galectins and Cancer Biology
- SARS-CoV-2 and COVID-19 Research
- Carbohydrate Chemistry and Synthesis
- Ubiquitin and proteasome pathways
- Polyamine Metabolism and Applications
- Animal Diversity and Health Studies
- Protein purification and stability
- Wound Healing and Treatments
- Prostate Cancer Treatment and Research
- Dermatologic Treatments and Research
King's College London
2014-2023
Guy's Hospital
2015-2021
Institut National de la Transfusion Sanguine
2013-2015
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy
2010-2015
Inserm
2010-2015
King's College Hospital
2015
The London College
2014
Polish Academy of Sciences
2010-2013
Laboratory of Excellence GR-Ex
2013
Rare polyagglutinable NOR erythrocytes contain three unique globoside (Gb4Cer) derivatives, NOR1, NORint, and NOR2, in which Gal(α1–4), GalNAc(β1–3)Gal(α1–4), Gal(α1–4)GalNAc(β1–3)Gal(α1–4), respectively, are linked to the terminal GalNAc residue of Gb4Cer. NOR1 both terminate with a Gal(α1–4)GalNAc- sequence, react anti-NOR antibodies commonly present human sera. While searching for an enzyme responsible biosynthesis Gal(α1–4)GalNAc, we identified mutation A4GALT gene encoding Gb3/CD77...
Objectives To identify cytokines that can activate and expand NK cells in the presence of prostate cancer order to determine whether these agents may be useful future intra‐tumoural administration pre‐clinical clinical trials. Materials Methods Lymphocytes isolated from normal donor blood were set up co‐cultures with either or non‐cancerous cell lines, together each interleukin (IL)‐2, IL‐12, IL‐15, interferon (IFN)‐γ IL‐21 for a period 7 days. Then, expansion cells, NKT CD8 T was measured...
Background: The prostate cancer microenvironment is highly immunosuppressive; immune cells stimulated in the periphery by systemic immunotherapies will be rendered inactive once entering this environment. Immunotherapies for need to break tolerance. We have previously identified interleukin-15 (IL-15) as only cytokine tested that activates and expands presence of cells. In current study, we aimed identify a method boosting efficacy IL-15 cancer. Methods: engineered, conjugation myristoylated...
Allograft transplantation into sensitized recipients with antidonor antibodies results in accelerated antibody-mediated rejection (AMR), complement activation, and graft thrombosis. We have developed a membrane-localizing technology of wide applicability that enables therapeutic agents, including anticoagulants, to bind cell surfaces protect the donor endothelium. describe here how this has been applied thrombin inhibitors generate novel class drugs termed thrombalexins (TLNs). Using rat...
Duffy Antigen Receptor for Chemokines (DARC) plays multiple roles in human health as a blood group antigen, receptor chemokines and the only known Plasmodium vivax merozoites. It is target of murine anti-Fy6 monoclonal antibody 2C3 which binds to first extracellular domain (ECD1), but exact nature recognized epitope was subject contradictory reports. Here, using set complex experiments include expression DARC with amino acid substitutions within Fy6 E. coli K562 cells, ELISA, surface plasmon...
Interleukin-15 (IL-15) is a cytokine previously suggested as potential immunotherapy for cancer treatment. IL-15 can effectively reduce tumor growth in many preclinical models including prostate cancer. This due to its ability expand and activate immune cells, such CD8+ T cells natural killer cells. To increase the potency of IL-15, we have engineered protein variant that be modified localize retained tissues where it administered. However, production recombinant purity, correct refolding...
Abstract Collectin-11 is a soluble C-type lectin produced at epithelial surfaces to initiate pathogen elimination by complement. Given the respiratory epithelium source of CL-11 and downstream complement-pathway components, we investigated potential impact pathogenicity SARS-CoV-2. While SARS-CoV-2 spike trimer could bind trigger complement activation followed MAC formation, virus was resistant lysis. Surprisingly, production infected cells enhanced opsonisation but this effect fully...
Abstract Introduction & Objectives: Prostate cancer progression can arise by tolerance to, and evasion of tumor cells from immune effector such as CD8 T NK due to the immunosuppressive microenvironment. Immunotherapeutic drugs eliminate tumors breaking this tolerance, that be localized prostate will have greater efficacy less systemic toxicity than administered systemically. It has also been shown a stimulation system boost immunity all over body clear distant metastases. However, in...
You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III1 Apr 2016MP84-07 A TALE OF TAILS – NOVEL APPROACH TO IMMUNOTHERAPY PROSTATE CANCER Christine Galustian, Dorota Smolarek, Christina Sakellariou, Oussama Elhage, Richard Smith, and Prokar Dasgupta GalustianChristine Galustian More articles by this author , SmolarekDorota Smolarek SakellariouChristina Sakellariou ElhageOussama Elhage SmithRichard Smith DasguptaProkar View All Author...
Abstract Introduction & Objectives: Prostate cancer progression can arise by tolerance to, and evasion of tumour cells from immune effector such as CD8 T NK due to the immunosuppressive microenvironment. Immunotherapeutic drugs eliminate tumours breaking this tolerance, that be localized prostate will have greater efficacy less systemic toxicity than administered systemically. It has also been shown a stimulation system boost immunity all over body clear distant metastases. However, in...
Abstract The immunosuppressive prostate cancer microenvironment renders most infiltrating effector immune cells anergic or regulatory. Immunotherapeutic agents localized to the can break this tolerance, leading greater efficacy and less toxicity than systemically administered drugs. We have previously shown that cytotopic modification of interleukin-15 (cyto-IL-15) activate NK CD8+ T-cells in presence cells. In present study, we used cyto-IL-15 two immuno-checkpoint blocking antibodies...